ebastine has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jeon, S | 1 |
| Ko, M | 1 |
| Lee, J | 1 |
| Choi, I | 1 |
| Byun, SY | 1 |
| Park, S | 1 |
| Shum, D | 1 |
| Kim, S | 1 |
| Palma, G | 1 |
| Pasqua, T | 1 |
| Silvestri, G | 1 |
| Rocca, C | 1 |
| Gualtieri, P | 1 |
| Barbieri, A | 1 |
| De Bartolo, A | 1 |
| De Lorenzo, A | 1 |
| Angelone, T | 1 |
| Avolio, E | 1 |
| Botti, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Silver Nanoparticles as an Oropharyngeal Product (Mouthwash) and Nasal Hygiene, by Health Personnel Working at the Tijuana General Hospital Exposed to Patients Diagnosed With Atypical Pneumonia Caused by SARS-CoV-2[NCT04894409] | 231 participants (Actual) | Interventional | 2020-04-24 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ebastine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
PI3Kδ Inhibition as a Potential Therapeutic Target in COVID-19.
Topics: Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; | 2020 |
1 other study available for ebastine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiop | 2020 |